Licence Agreement Supports Pre-Clinical Drug Projects

An agreement for the use of two commercial licences for Horizon’s proprietary GS knockout CHO cell line has been signed by Shanghai-based Sanyou Biopharmaceuticals Co. Ltd, for development of pre-clinical antibody drug projects and to support its customers’ human biotherapeutic products, as well as offering the platform through its contract research services.

“Sanyou is a leading biotechnology company with extensive experience in early stage drug discovery, IND filing and clinical trial management. The Company has established an integrated innovative antibody drug R&D laboratory and we are pleased CHOSOURCE has been selected to support its biotherapeutic pipeline and contract research services offering,” commented Jesús Zurdo, Global Head Bioproduction Business Unit, Horizon Discovery. “Horizon is committed to supporting innovative organisations of all sizes to empower biotherapeutic production using our expression platform. We are proud to have licensed CHOSOURCE to over 80 organisations, from non-for-profit and early stage startups to clinical stage biotechnology and large pharmaceutical companies and helped enable at least 8 biotherapeutics expressed in these cells to progress into clinical trials.”

Dr. David Lang, CEO, Sanyou Biopharmaceuticals Co., Ltd., said: “Horizon’s CHOSOURCE facilitates the development of stable cell lines for the expression of antibodies and other recombinant proteins, and is recognised in the industry and by regulators for high yield manufacturing. This robust platform will be key in enabling us to generate stable cell lines for the development of antibody drugs, diagnostic products and cell therapy-related components, and allow us to provide a stronger one-stop solution to our clients with IND ready projects through our contract research services and pipeline-enriching collaborations.”